AI in Drug Discovery Market Projected to Reach $25.0 Billion by 2035
The AI in drug discovery market is expected to reach USD 25.0 billion by 2035, growing at a CAGR of 12.6%, according to a report by Roots Analysis. The expansion is driven by rising R&D investments and increasing biomedical datasets.
The global market for artificial intelligence (AI) in drug discovery is projected to reach USD 25.0 billion by 2035, expanding at a compound annual growth rate (CAGR) of 12.6%, according to a new report by Roots Analysis.
AI is transforming the traditionally lengthy and inefficient process of drug candidate identification. By leveraging advanced computational technologies, AI-based platforms enhance precision, reduce failure rates, and accelerate development timelines. These tools facilitate rapid analysis of diverse datasets for target identification and molecular optimization, streamlining the path from research to clinical application.
Key drivers fueling this market growth include the rising prevalence of chronic diseases, necessitating faster therapeutic development, and the increasing availability of large-scale biomedical datasets such as genomics data. Robust investments in AI-enabled research and development, coupled with venture capital funding, are also fostering the creation and commercialization of new AI platforms.
However, the market faces potential restraints such as data privacy and security concerns related to sensitive patient information. High upfront costs for advanced infrastructure and a shortage of skilled professionals to manage complex AI models may also impact the scalability and widespread adoption of AI-based drug discovery solutions.